SubscribeorLogin

PCOS Notes

by | Jan 19, 2015

Post Categories: Uncategorized

Notes

  1. Marchese M. Polycystic ovarian syndrome: a natural treatment approach. Townsend Lett. Feb/March 2012:66–68.
  2. Guzick D. Polycystic ovarian syndrome. Obstet Gynecol. 2004;103(1):181–193.
  3. Romm A. Botanical Medicine for Women’s Health. St. Louis: Churchill Livingstone/Elsevier; 2010:175–185.
  4. Wei A et al. Therapy for polycystic ovarian syndrome. Curr Opin Pharmacol. 2003;3:678–682.
  5. Ring M. Polycystic ovarian syndrome. In: Rakel D. Integrative Medicine. 3rd ed. Philadelphia: Elsevier;2012:345–352.
  6. Azziz R. Androgen excess is the key element in polycystic ovary syndrome. Fertil Steril. 2003;80:252–254.
  7. Azziz R et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–2782.
  8. Balen A et al. Polycystic ovary syndrome: the spectrum of this disorder in 1741 patients. Hum Reprod. 1995;10:2107–2111.
  9. Book C et al. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 199;84(9):3110–3116.
  10. Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin dependent diabetes mellitus. Am J Med. 1995;98:33S–39S.
  11. Tsilchorozidou T et al. The pathophysiology of polycystic ovary syndrome.
    Clin Endocrinol (Oxf). 2004;60:1–17.
  12. Richardson M. Current perspective in polycystic ovary syndrome. Am Fam Physician. 2003;68(4):697–704.
  13. Alexander C. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol. 2009;2(4):232–239.
  14. Marchese. Op cit.
  15. Speroff. Op cit.
  16. Solomon C. The epidemiology of polycystic ovary syndrome: prevalence and associated disease risks. Endocrinol Metab Clin North Amer. 1999;28(2):247–263.
  17. Fraser I et al. Current recommendations for the diagnostic evaluation and follow-up of patients presenting with symptomatic polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18(5):813–823.
  18. Ahene S et al. Polycystic ovary syndrome. Nurs Stand. 2004;18(26):40–44.
  19. Futterweit W. A Patient’s Guide to PCOS. New York: Henry Holt and Company; 2006.
  20. Marchese. Op cit.
  21. Carmina E. Diagnosing PCOS in women who menstruate regularly. Contemp Obstet Gynecol. 2003;53–64.
  22. Marchese. Op cit.
  23. Hill, K., Update: the pathogenesis and treatment of PCOS. Nurse Pract 2003;28:8–25.
  24. Romm. Op cit.
  25. Marchese. Op cit.
  26. Pritts E. Treatment of the infertile woman with polycystic ovarian syndrome. Obstet Gynecol Surv. 2002;57:587–597.
  27. Futterweit. Op cit.
  28. Atimo W et al. Familial associations in women with polycystic ovary syndrome. Fertil Steril. 2003;80(1):143–145.
  29. Gonzalez C et al. Polycystic ovaries in childhood: a common finding in daughters of PCOS patients of PCOS patients. A pilot study. Hum Reprod. 2002;17(3):771–776.
  30. Govind A et al. Polycystic ovaries are inherited as an autosomal dominant trait: an analysis of 29 polycystic ovary and 10 control families. J Clin Endocrinol Metab. 1999;84:38043.
  31. Futterweit. Op cit.
  32. Azziz R et al. Family history as a risk factor for the polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2000;13:1303–1306.
  33. Strauss J et al. Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome. Ann NY Acad Sci. 2003;997:42–48.
  34. Carey A et al. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol. 38(6):653–658.
  35. Urbanek M et al. Thirty seven candidate genes for PCOS: Strongest evidence of linkage is follistatin. Proc Nat Acad Sci. 1999;38(6):653–658.
  36. King J. Polycystic ovarian syndrome. J Midwifery Womens Health. 2006;51(6):415–422.
  37. King. Ibid.
  38. Tsilchorozidou. The pathophysiology of polycystic ovary syndrome. 2004. Op cit.
  39. Marchese. Op cit.
  40. Speroff. Op cit.
  41. Romm. Op cit.
  42. Speroff. Op cit.
  43. Hopkinson Z et al. Polycystic ovarian syndrome: the metabolic syndrome comes to gynecology. BMJ. 1998;317:329–332.
  44. Marchese. Op cit.
  45. Romm. Op cit.
  46. Marantides D et al. Management of polycystic ovary syndrome. Nurse Pract. 1997;22(12):34–38,40–41.
  47. Tsilchorozidou T et al. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates. J Clin Endocrinol Metab. 2004;88(12):5907–5913.
  48. Barnea E et al. Stress-related reproductive failure. J In Vitro Fert Embryo Transf. 1991;8:15–23.
  49. Tsilchorozidou T et al. The pathophysiology of polycystic ovarian syndrome. 2004. Op cit.
  50. Lindsay A et al. Multicystic ovaries in primary hypothyroidism. Obstet Gynecol. 1983;61:433–437.
  51. Ghosh S et al. Subclinical hypothyroidism: a determinant of polycystic ovary syndrome. Horm Res. 1993;39:61–66.
  52. McNamara D. Thyroiditis rate three-fold higher with PCOS. Fam Pract News. 2004;Mar 1:75.
  53. Marchese. Op cit.
  54. Chang R et al. Normal ovulatory women with polycystic ovaries have hypoandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing. J Clin Endocrinol Metab. 2000;85(3):995–1000.
  55. Pelusi B et al. Type 2 diabetes and the polycystic ovary syndrome. Minerva Ginecol. 2004;56(1):41–51.
  56. Talbott E et al. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Amer. 2001;28(1):111–133.
  57. Rajkhowa M et al. Polycystic ovary syndrome: a risk for cardiovascular disease. BJOG. 2000;107(1):11–18.
  58. Trent M et al. Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome: implications for quality of life. J Pediatr Adolesc Gynecol. 2003;16(1):33–37.
  59. Radulovic A et al. Obesity and hormone function changes in female patients with polycystic ovaries. Med Pregl. 2003;56(9–10):476–480.
  60. Gonzalez, C et al. Polycystic ovarian disease: clinical and biochemical expression. Ginecol Obstet Mex. 2003;71:253–258.
  61. Pelusi B et al. Type 2 diabetes and the polycystic ovary syndrome. Minerva Ginecol. 2004;56(1):41–51.
  62. Legro R et al. Prevalence and predictors of risk for Type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metabol. 1999;84(1):165–169.
  63. De Leo, V et al. Polycystic ovary syndrome and type 2 diabetes mellitus. Minerva Ginecol. 2004;56(1):53–62.
  64. Solomon C et al. Long or irregular menstrual cycle as a marker for the risk of type 2 diabetes mellitus. JAMA. 2001;286(19):2421–2426.
  65. Solomon. Op cit.
  66. Danaif A et al. Beta cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81:942–947.
  67. Christian R et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88(6):2562–2568.
  68. Wild S et al. Cardiovascular disease in women with PCOS: A long-term follow up: A retrospective cohort study. Clin Endocrinol (Oxf). 2000;52(5):595–600.
  69. Talbot, E et al. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Amer. 2001;28(1):111–133.
  70. Marchese. Op cit.
  71. Orio F et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab. 2004;89(8):3696–3701.
  72. Marchese. Op cit.
  73. Chang R. A practical approach to the diagnosis of polycystic ovary syndrome. Am J Obstet Gynecol. 2004;191:713–717.
  74. Phelan N et al. Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS. J Clin Endocrinol Metab. 2010;95(8):3933–3939.
  75. Wild R et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) society. Fertil Steril. 20011;95(3):1073–79.
  76. Ehrmann D. Polycystic ovarian syndrome. N Eng J Med. 2005;353:1223–1236.
  77. Romm. Op cit.
  78. Loverro G et al. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest. 2002;53(3):157–162.
  79. Boulman N et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metabol. 2004;89(5):2160–2165.
  80. Fenkev I et al. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003;8091):123–127.
  81. Lefebvre, P et al. Long-term risks of polycystic ovaries syndrome. Gynecol Obstet Fertil. 2004;32(3):193–198.
  82. Landsberg M. Insulin sensitivity in the pathogenesis of hypertension and hypertensive complications. Clin Exp Hypertens. 1996;18(3–4):337–346.
  83. Milsom S et al. LH levels in women with polycystic ovarian syndrome: have modern assays made them irrelevant? BJOG. 2003;110(8):760–764.
  84. Franks S. The ubiquitous polycystic ovary. J Endocrinol. 1991;129:317–319.
  85. Diejomaoh M et al. The relationship of recurrent spontaneous miscarriage with reproductive failure. Med Princ Pract. 2003;12(2):107–111.
  86. Rai R et al. Polycystic ovaries and recurrent miscarriage – a reappraisal. Hum Reprod. 2000;15:612–615.
  87. Hardiman P et al. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003;361(9371):1810–1812.
  88. Spremovi R et al. The polycystic ovary syndrome associated with ovarian tumor. Srp Arh Celok Lek. 1997;125 (11–12):375–377.
  89. Wild S et al. Long-term consequences of polycystic ovary syndrome: results of a 31-year study. Hum Fertil (Camb). 2000;3(2):101–105.
  90. Robinson S et al. Postprandial thermogenesis is reduced in polycystic ovary syndrome and is associated with increased insulin resistance. Clin Endocrinol (Oxf). 1992;36(6):537–543.
  91. Faloia E et al. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest. 2004;27(5):424–429.
  92. Gambineri A et al. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002;26(7):883–896.
  93. Romm. Op cit.
  94. Wei. Op cit.
  95. Richardson. Op cit.
  96. Speroff. Op cit.
  97. Guzick D. Polycystic ovary syndrome: symptomatology, pathophysiology, and epidemiology. Am J Obstet Gynecol. 1998;196(6 Pt. 2):S89–S93.
  98. D’Hooghe T et al. Infertility. In: Novak’s Gynecology. Philadelphia: Lippincott Williams & Wilkins; 2002.
  99. Fleming R et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double-blind placebo controlled trial. J Clin Endocrinol Metabol. 2003;87(2):557–569.
  100. Lord J et al. Insulin-sensitizing drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovarian syndrome. Cochrane Database Syst Rev. 2003:3:(CD003053).
  101. McCarthy E et al. Metformin in obstetric and gynecologic practice: a review. Obstet Gynecol Surv. 2004; Huber-Buchholz M et al. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 1999;84(4):1470–1474.
  102. Anderson J et al. Dietary fiber: diabetes and obesity. Am J Gasteroenterol. 1986;81:898–906.
  103. Burke V. Dietary protein and soluble fiber reduce ambulatory blood pressure in treatment of hypertensives. Hypertension. 2001;38(4):821–826.
  104. Sprecher D et al. efficacy of psyllium in reducing serum cholesterol levels in hypercholesterolemic patients on high-or low-fat diets. Ann Inter Med. 1993;119:545–554.
  105. Huber-Buchholz. Op cit.
  106. Richardson. Op cit.
  107. Romm. Op cit.
  108. Solomon. Op cit.
  109. D’Hooghe. Op cit.
  110. Crosignani P et al. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate by diet. Human Reprod. 1932;18(9):1928–1932.
  111. Jakubowicz D et al. 17-alpha-hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metabol. 1997;82(2):556–560.
  112. Kahn J et al. Polycystic ovary syndrome. Adolesc Med. 1999;10(2):231–236.
  113. Pasquali R et al. Weight control and its benefits on fertility in women with obesity and polycystic ovary syndrome. Hum Reprod. 1997;12 (Suppl 1):82–87.
  114. Van Dam, E et al. Increase in daily LH secretion in response to short-term caloric restriction in obese women. Am J Physiol Endocrinol Metab. 2001;282:865–872.
  115. Ring. Op cit.
  116. Palomba S et al. Structured exercise training programme versus hypocaloric hyperproteinemic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-233k pilot study. HumReprod. 2008;23:642–650.
  117. Bland, J., Introduction to neuroendocrine disorders. Functional Medicine Approaches to Endocrine Disturbances of Aging. Gig Harbor, WA: Functional Medicine Institute; 2001:121.
  118. Kasim Karakas M et al. Metabolic and endocrine effects of a polyunsaturated fatty acid-rich diet in polycystic ovary syndrome. J Clin Endocrinol Metabol. 2004;89(2):615–620.
  119. Chan J et al. Water, other fluids, and fatal coronary heart disease. Am J Epidemiol. 2002;155(9):827–833.
  120. Thys-Jacobs S et al. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids. 1999;64(6):430–435.
  121. Nestler J et al. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Eng J Med. 1999;340:1314–1320.
  122. Baillargeon J et al. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care. 2006;29:300–305.
  123. Gaby A. Nutritional Medicine. Concord, NH: Fritz Perlberg Publishing; 2011:829–831.
  124. Davis A et al. Effect of pinitol treatment on insulin action in subjects with insulin resistance. Diabetes Care. 2000;23:1000–1005.
  125. Ring. Op cit.
  126. Badawy A et al. N-acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a cross-over trial. Acta Obstet Gynecol Scand. 2007;86:218–222.
  127. Rizk S et al. N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil Steril. 2005;83:367–370.
  128. Low Dog T. The endocrine system. In: Foundations in Herbal Medicine. Albuquerque: Foundations in Herbal Medicine; 2000.
  129. Mills. Op cit.
  130. McKenna D et al. Botanical Medicines: The Desk Reference for Major Herbal Supplements. New York: Haworth Press; 2002.
  131. Wuttke W et al. Chaste tree (Vitex agnus castus): pharmacology and clinical indications. Phytomedicine. 2003;10:348–357.
  132. Westphal L et al. A nutritional supplement for improving fertility in women: a pilot study. J Reprod Med. 2004;49:289–293.
  133. Westphal L et al. Double-blind, placebo-controlled study of Fertilityblend: a nutritional supplement for improving fertility in women. Clin Exp Obstet Gynecol. 2006;33:205–208.
  134. Marchese. Op cit.
  135. Pais P. Potency of a novel saw palmetto ethanol extract, SPET-O85, for inhibition of 5alpha-reductase II. Adv Ther. 2010;27(8):555–563.
  136. Vassiliandi D et al. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94:3558–3566.
  137. Chrubasik J et al. A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix. Phytomedicine. 2007;14(7–8):568–579.
  138. Urtica dioica; Urtica urens (nettle) [monograph]. Altern Med Rev. 2007;12(3):280.
  139. Marchese. Op cit.
  140. Nagata C et al. Association of coffee, green tea, and caffeine intakes with serum concentrations of estradiol and sex hormone-binding globulin in premenopausal Japanese women. Nutr Cancer. 1998;30(1):21–24.
  141. Chan C et al. Effect of Chinese green tea on weight, and hormonal and biochemical profiles in obese patients with polycystic ovary syndrome: a randomized placebo controlled trial. J Soc Gynecol Investig. 2006; Jan 13:63–68.
  142. Ibid.
  143. Marchese. Op cit.
  144. Amanini D et al. History of the endocrine effects of licorice. Exp Clin Endocrinol Diabetes. 2002;110(6):257–261.
  145. Amanini D et al. Licorice reduces serum testosterone in healthy women. Steroids. 2005;69:763–66.
  146. Grant P et al. Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial. Phytother Res. 2010;24:186–188.
  147. Chen J et al. Maitake mushroom (Grifola frondosa) extract induces ovulation in patients with polycystic ovary syndrome: a possible monotherapy and a combination therapy after failure with first-line clomiphene citrate. J Altern Complement Med. 2010;16(12):1295–1299.
  148. Marchese. Op cit.
  149. Yang H et al. Paeoniflorin: an antihyperlipidemic agent from Paeonia lactiflora. Fitoterapia. 2004;7591):45–49.
  150. Hsu F et al. Antihyperglycemic effects of paeoniflorin and S-debenzoylpaeoniflorin, glucosides from the root of Paeonia lactiflora. Planta Medica. 1997;63(4):323–325.
  151. Takahashi K et al. Effects of TJ-68 (shakuyaku-kanzo-to) on polycystic ovarian disease. Int J Fertil Menopausal Stud. 1994;39(2):69–76.
  152. Lim C et al. Current evidence of acupuncture on polycystic ovarian syndrome. Gynecol Endocrinol. 2010;26:473–478.
  153. Stener-Victorin E et al. Low-frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome. Am J Physiol. 2009;297:R387–R395.
  154. Eid G et al. Effective treatment of polycystic ovarian syndrome with Roux-en Y gastric bypass. Surg Obes Relat Dis. 2005;1:77–80.

Register below to read this article, free!

Create a free account to access this content and get more of Townsend Letter's top stories directly to your inbox.

Or, subscribe for full access.

Return to Previous Page or Log in.

Already Subscribed?

Log In

Search

Formatting updates are ongoing for older articles.

Author

Townsend Letter

Featured Articles

Where are your Clinical Trials?

It has proven to be difficult, if not impossible, to proceed to full-scale randomized controlled trials (RCTs) for most of the natural methods that cannot be patented or otherwise monopolized. 

A Renewed Focus on Self-Help for Healing

As the producer of The Moss Report, the year leading up to the Covid-19 pandemic was filled with anticipation and excitement. We had invested years of hard work and significant resources into two major projects: our feature film, Immunotherapy: The Battle Within, and...

Issue Archives

Event Calendar

Events

Today

  • 2026 Association of Natural Health Conference

    Douglasville Conference Center Douglasville, GA, United States

    "From Practitioner to Leader: Clinical Excellence, Business Mastery & Sustainable Practice" Discover how clinical excellence, business mastery, and sustainable systems can help practitioners grow into confident leaders and build practices designed for long-term impact. Why Attend? Three days of learning, connection, and growth designed for every stage of your practice journey. Learn from Leading Voices Gain insights from top experts in natural health, holistic wellness, and functional medicine. Hands-On Learning Participate in in-depth workshops, real-world case studies, and interactive sessions you can apply immediately. Meaningful Networking Connect with like-minded professionals, students, and exhibitors who share your passion for natural health. Practical Tools & Approaches Explore new strategies and tools to elevate both your practice and your own health journey. Who Should Attend? This conference is built for a wide community of natural health professionals, educators, and advocates - wherever you are in your journey. Licensed & Clinical Practitioners Doctors, chiropractors, acupuncturists, naturopaths, and functional or integrative medicine practitioners looking to sharpen clinical skills and grow into stronger practice leaders. Allied Health Professionals Bio-feedback technicians and other allied practitioners seeking hands-on training and the latest tools in natural and holistic care. Educators & Students Natural health educators and students entering the […]

  • Food as Medicine Global 2026

    Virtual Event

    Join health professionals, farmers, food producers, researchers, educators, nonprofit leaders, chefs, policymakers, community organizers, food advocates, public health practitioners, nutritionists, and other changemakers as we convene to share knowledge, build partnerships, and explore new possibilities for improving health, strengthening communities, and creating more equitable and sustainable food systems. This year’s program features inspiring speakers and practical examples of collaboration at the intersection of food, health, social justice, and planetary well-being. Together, we’ll explore innovative approaches to Food as Medicine, community-led initiatives, nutrition, public health, regenerative agriculture, and equitable access to healthy food. Whether you work in health care, agriculture, food production, education, research, policy, or community development, you will discover new ideas, meaningful connections, and practical strategies to advance healthier, more resilient communities. Virtual  |  Join from anywhere in the world Check out the Program: https://tinyurl.com/Food-as-Medicine-for-All

  • The Midlife Women’s Health Summit: Evidence-Based Menopause Care in the Era of Longevity Medicine

    The Ritz-Carlton, Pentagon City 1250 S Hayes St, Arlington, VA, United States
    Hybrid Event

    Menopause Care in the Longevity Era Longevity medicine is everywhere right now. Supplements, protocols, influencer clinics, patients walking in with questions about interventions their doctors have never heard of. What's missing from most of it is the evidence. The Midlife Women's Health Summit is three days on what the research actually says about menopause care when you add a longevity lens. What works, what doesn't, what's being oversold, and what to tell the patient sitting in front of you. Co-chaired by Lisa Larkin, MD, FACP, MSCP, IF, Jen Gunter, MD, FRCS(C), FACOG, DABPM, ABPMR, and Lauren Streicher, MD, FACOG, MSCP; three of the clearest voices in women's health on separating data from marketing.

    $995 – $1299

Full Event Calendar

Submit Your Event

Related Posts

You Deserve a Beautiful Life

by Gary Null, PhD – How many times have we gone against the current of our own being? You know you should do A, but you are conditioned to do B.

You are fighting it because the conditioned self is conditioned from a place of fear. And fear will always win if we give in to it.

Read More

Aug 31, 2026

Increase Sperm Count, Improve Fertility and Decrease Cancer Risk

By Erik Peper, PhD – The recently released Netflix documentary The Plastic Detox offers an eye-opening exploration of the hidden dangers of the chemicals in plastics in our homes and daily lives. It highlights concerns ranging from hormone disruption—which may contribute to declining fertility worldwide—to increasing rates of cancer and earlier occurrences of heart attack and stroke.

Read More

Jun 30, 2026

A Powerful New (and Old!) Treatment for Pain, POTS, MCAS, Lyme and Postinfectious Fibromyalgia

by Jacob Teitelbaum, MD – “PEA is thought to be produced as a protective response to cellular injury…effects include…analgesic, anticonvulsant, antimicrobial,…immunomodulatory and neuroprotective activities. PEA’s multi-faceted effects are due to its unique mechanisms of action.” It also helps your immune system with viruses, bacteria, and “leaky gut.”

Read More

Jan 31, 2026

0 Comments

Submit a Comment